PTC Therapeutics (PTCT) Buy Rating Maintained at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
PTC Therapeutics (PTCT) Pares Move Higher Following M&A Speculation (BMRN)
February 23, 2015 12:28 PM ESTPTC Therapeutics (NASDAQ: PTCT) is paring some gains related to M&A speculation. One noted biotech watcher thinks a move for BioMarin (Nasdaq: BMRN) to acquire PTCT is unlikely.
$BMRN is interested in buying $PTCT? Thats hard to believe.
— Adam Feuerstein (@adamfeuerstein) February 23, 2015... More
UPDATE: PTC Therapeutics (PTCT) pops; said to be exploring possible sale - Reuters
February 23, 2015 12:03 PM EST(Updated - February 23, 2015 12:43 PM EST)
PTC Therapeutics (NASDAQ: PTCT) pops on chatter the company is exploring a sale, according to Reuters headlines.
According to the report, the company has received takeover interest from several pharmaceutical companies including Shire plc (NASDAQ:... More
